Investors

Investor Relations Policy

 

To Pharma Equity Group, openness and transparency are essential in maintaining good relations with investors. The company aims to give the market open, satisfactory information about the company’s operations, strategy and results with a view to ensuring fair pricing of the share and to contribute to ensuring good corporate governance.

All stakeholders should have fast, equal access to important information about the company’s development and growth. One of the ways this is effectuated is by publicizing in-house knowledge in company announcements to Nasdaq Copenhagen, which are subsequently made available at the company’s website, www.pharmaequitygroup.com.

Investors and other interested parties can sign up for notification of published company announcements, newsletters and other material in the investor section of the website. Other publicized information, including general corporate and investor presentations, are made available to the general public on the website.

To ensure an efficient, expedient dialog with our shareholders, the company encourages its shareholders to let their shareholding be registered and to participate in Annual General Meetings. Investor Relations is also responsible for ensuring that information from the company’s IR stakeholders is passed on to the Management and the Board of Directors of the Company.

Thomas Kaas Selsø, Incoming CEO

Tel.: +4540222114

Thomas.kaas.selsoe@pharmaequitygroup.com

 

Company Profile

 

Pharma Equity Group is a listed company on the Nasdaq Copenhagen Stock Exchange, with a focus on early investment in innovative life science companies (in or before phase 2) that develop technologies and therapies that have the potential to improve human health and quality of life.  The Team consists of experienced professionals with a background in the life science industry as well as in investment and business development.  In addition, Pharma Equity Group has a strong network of industry partners and advisors.

Our team consists of experienced professionals with backgrounds in the life science industry, as well as in investment and business development. We have a strong network of industry partners and advisors and are committed to collaborating with our portfolio companies to help them achieve their goals.

Investment Focus: We specialize in early-stage investments in the biotechnology (Prior to phase 2). We are particularly interested in companies that are developing novel therapies for unmet medical needs.

Our portfolio currently includes a Reponex Pharmaceuticals A/S. Reponex Pharmaceuticals A/S is a clinical-stage biopharmaceutical company dedicated to the development of new, effective treatments for diseases that have significant patient and social impact for which current therapy is lacking or in need of improvement. The strategy creates a cost efficient and flexible way to create relevant humane ressources fast, which is considered a key factor and drives success.